MOBKL2A function by modulating the intracellular levels of cyclic AMP (cAMP), which is a pivotal secondary messenger in various signaling pathways. Forskolin directly stimulates adenylate cyclase, the enzyme responsible for the conversion of ATP to cAMP, thus increasing the concentration of cAMP within the cell. This surge in cAMP activates protein kinase A (PKA), which then phosphorylates and activates MOBKL2A. Similarly, prostaglandin E1 (PGE1) engages with its specific receptor to enhance adenylate cyclase activity, thereby elevating cAMP levels and subsequently activating PKA to phosphorylate MOBKL2A. Furthermore, IBMX, a non-selective inhibitor of phosphodiesterases, prevents the breakdown of cAMP, which leads to an accumulation of this messenger molecule and the activation of PKA, culminating in the phosphorylation of MOBKL2A.
PDE inhibitors like cilostamide and anagrelide specifically target PDE3, whereas rolipram selectively inhibits PDE4, and zardaverine inhibits both PDE3 and PDE4. These interventions impede the degradation of cAMP, leading to its accumulation and the subsequent activation of PKA. As a result, PKA can then phosphorylate MOBKL2A. Milrinone, another PDE3 inhibitor, operates in a similar fashion, boosting cAMP levels to facilitate the activation of PKA and the phosphorylation of MOBKL2A. Sildenafil, though primarily known for targeting PDE5, also affects cAMP levels in certain tissues, enabling PKA to phosphorylate MOBKL2A. Dipyridamole has a broader range of action, inhibiting various phosphodiesterases including PDE3, and thus it also contributes to the elevation of cAMP and the activation of PKA, which phosphorylates MOBKL2A. Trequinsin potently inhibits PDE3, resulting in increased cAMP levels and the subsequent activation of PKA and phosphorylation of MOBKL2A. Vincristine, unique among the listed chemicals, disrupts microtubule formation and can activate stress-activated protein kinases, which may interact with and lead to the activation of MOBKL2A as part of the cellular stress response.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) inhibits phosphodiesterases, preventing cAMP degradation, thereby enhancing PKA activity which subsequently activates MOBKL2A through phosphorylation. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Prostaglandin E1 (PGE1) binds to its receptor, increasing cAMP production via adenylate cyclase activation, and thus, PKA activation, leading to the phosphorylation and activation of MOBKL2A. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide inhibits PDE3, leading to increased cAMP levels, which enhance PKA-mediated phosphorylation and activation of MOBKL2A. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits PDE4, which results in increased cAMP levels, and thereby activates PKA that can phosphorylate and activate MOBKL2A. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits PDE3, increasing cAMP concentration, thus activating PKA which in turn can phosphorylate and activate MOBKL2A. | ||||||
Zardaverine | 101975-10-4 | sc-201208 sc-201208A | 5 mg 25 mg | $88.00 $379.00 | 1 | |
Zardaverine is a PDE3 and PDE4 inhibitor, which raises cAMP levels, thereby activating PKA that can phosphorylate and activate MOBKL2A. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone selectively inhibits PDE3, leading to increased cAMP levels, thus promoting PKA activity which can lead to MOBKL2A activation through phosphorylation. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole inhibits phosphodiesterases, including PDE3, leading to elevated cAMP levels and subsequent activation of PKA which can phosphorylate and activate MOBKL2A. | ||||||